4.71

9.08% -0.52

After Hours: 4.76 0.05 +1.06%

Portage Biotech Inc (PRTG)

Overview News Price History Option Chain Why PRTG Down? Discussions Forecast Stock Split

Portage Biotech Inc stock is traded at $4.71, with a volume of 49,573. It is down -9.08% in the last 24 hours and down -4.71% over the past month. Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Previous Close:

$5.23

Open:

$4.97

24h Volume:

49,573

Relative Volume:

0.08

Market Cap:

$8.16M

Revenue:

Net Income/Loss:

$-67.28M

P/E Ratio:

-0.0498

EPS:

-94.66

Net Cash Flow:

$-9.80M

1W Performance:

+7.82%

1M Performance:

-4.71%

6M Performance:

+47.76%

1Y Performance:

-63.97%

1-Day Range:

$4.60

$5.24

1-Week Range:

$3.80

$5.30

52-Week Range:

$2.098

$23.01

Portage Biotech Inc Stock (PRTG) Company Profile

Name

Portage Biotech Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-12-26

Latest SEC Filings

PRTG's Discussions on Twitter

Compare PRTG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRTG Portage Biotech Inc	4.71	8.16M	0	-67.28M	-9.80M	-94.66
VRTX Vertex Pharmaceuticals Inc	469.23	122.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	710.00	78.30B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	646.64	39.73B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.19	35.50B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.61	28.47B	3.30B	-501.07M	1.03B	-2.1146

Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-07-22	Initiated	H.C. Wainwright	Buy
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-02-21	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight

Portage Biotech Inc Stock (PRTG) Latest News

Feb 04, 2025

What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News

Feb 04, 2025

Feb 03, 2025

Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph

Feb 03, 2025

Jan 30, 2025

Portage Biotech Secures $2.15 Million in Private Financing - TipRanks

Jan 30, 2025

Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times

Jan 30, 2025

Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq

Jan 30, 2025

Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan

Jan 30, 2025

Jan 11, 2025

Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World

Jan 11, 2025

Jan 07, 2025

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com

Jan 07, 2025

Jan 06, 2025

Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks

Jan 06, 2025

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company - The Manila Times

Jan 06, 2025

Portage Biotech Launches Cyncado Therapeutics to Pioneer Advanced Cancer Immunotherapy Development - StockTitan

Jan 06, 2025

Jan 01, 2025

(PRTG) Trading Signals - Stock Traders Daily

Jan 01, 2025

Dec 21, 2024

(PRTG) Trading Advice - Stock Traders Daily

Dec 21, 2024

Dec 19, 2024